MoelleringRCKrogstadDJGreenblattDJ. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis1981; 3(suppl):S230–5.
2.
WhitbyMEdwardsRAstonEFinchRG. Pharmacokinetics of single dose intravenous vancomycin in CAPD peritonitis. J Antimicrob Chemother1987; 19:351–7.
3.
CunhaBAQuintilianiRDeglinJMIzardMWNightingaleCH. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis1981; 3(suppl):S269–72.
4.
AnneLHuMChanKColinLGottwaldK. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: Its detection in sera of renally impaired patients. Ther Drug Monit1989; 11:585–91.
5.
HarrisCMKopeckaHHarrisTM. Vancomycin: Structure and transformation to CDP-1. J Am Chem Soc1983; 105:6915–22.
6.
HarrisCMHarrisTM. Structure of the glycopeptide antibiotic vancomycin. Evidence for an asparagine residue in the peptide. J Am Chem Soc1982; 104:4293–5.
7.
HuMWAnneLForniTGottwaldK. Measurement of vancomycin in renally impaired patient samples using a new high-performance liquid chromatography method with vitamin B12 internal standard: Comparison of high-performance liquid chromatography, EMIT, and fluorescence polarization immunoassay methods. Ther Drug Monit1990; 12:562–9.
8.
WhiteLOEdwardsRHoltHALoveringAMFinchRGReevesDS. The in-vitro degradation at 37 degrees Celsius of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J Antimicrob Chemother1988; 22:739–45.
9.
MorseGDNairnDKBertinoJSWalsheJJ. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit1987; 9:212–5.
10.
NoseworthyJH. Therapeutics of multiple sclerosis. Clin Neuropharmacol1991; 14:49–61.
11.
The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci1987; 14:173–8.
12.
MurrayTJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci1985; 12:251–4.
RosenbergGAAppenzellerO. Amantadine, fatigue, and multiple sclerosis. Arch Neurol1988; 45:1104–6.
15.
ScattonBCheramyABessonMJGlowinskiJ. Increased synthesis and release of norepinephrine and dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol1970; 13:131–3.
16.
CohenRAFisherM. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol1989; 46:676–80.
17.
ChibaSItoMMatsumotoH. Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis (letter). Can J Neurol Sci1992; 191:309.
PassHI. Treatment of malignant pleural and pericardial effusions. In: De-VitaVTHellmanSRosenbergSA, eds. Cancer, principles and practice of oncology. 3rd ed.Philadelphia: JB Lippincott, 1989:2317–27.
20.
TattersallMHNBoyerMJ. Management of malignant pleural effusions (editorial). Thorax1990; 45:81–2.
21.
RuckdeschelJCMooresDLeeJYEinhornLHMandelbaumIKoellerJ. Intrapleural therapy for malignant pleural effusions. Chest1991; 100:1528–35.
22.
SiftonDW, ed. Drug topics red book 1992. Montvale, NJ: Medical Economics Data, 1992:129, 415.
23.
KeffordRFWoodsRLFoxRMTattersallMHN. Intracavitary adriamycin, nitrogen mustard and tetracycline in the control of malignant effusions. Med J Aust1980; 2(suppl):447–8.
24.
BaylyTCKisnerDLSybertAMacdonaldJSTsouEScheinPS. Tetracycline and quinacrine in the control of malignant pleural effusions. A randomized trial. Cancer1978; 41:1188–92.
25.
MuschELoosUMackesKGSeitzerDWernerAPeissJ. Intrapleural mitoxantrone in the treatment of malignant pleural effusion. In: KreidlerJLinkKAignerK, eds. Advances in regional cancer therapy. Basel, Switzerland: Karger, 1988:184–9.
26.
TopuzEZissisNPDincerMOralEN. Intrapleural instillation of mitoxantrone in the treatment of malignant pleural effusions. Reg Cancer Treat1991; 3:323–5.
27.
GrothGGatzemeierUHaussingenKHeckmayerMMagnussenHNeuhaussR. Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann Oncol1991; 2:213–5.
28.
WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva: World Health Organization, 1979:18–9.
29.
PaarWDPetersDMuschEBodeU. Pharmacokinetics of intrapleurally administered mitoxantrone (poster). IV World Conference on Clinical Pharmacology and Therapeutics. Mannheim-Heidelberg, July 23–28, 1989.
30.
ReigerDABoydJHBurkeJDRaeDSMyersJKKramerM. One-month prevalence of mental disorders in the United States. Arch Gen Psychiatry1988; 45:977–86.
HalpernJKGlassmanAH. Adequate tricyclic treatment: Defining the tricyclic nonresponder. In: RooseSPGlassmanAH, eds. Treatment for refractory depression. Washington, DC: American Psychiatric Press, 1990:13–32.
33.
PotterWZRuderofMVManjiH. The pharmacologic treatment of depression. Drug Ther1991; 325:633–42.
34.
PreskornSHFastGA. Therapeutic drug monitoring for antidepressants: Efficacy, safety, and cost effectiveness. J Clin Psychiatry1991; 52(suppl):523–33.
35.
AmsterdamJBrunswickDMendelsJ. The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. Am J Psychiatry1980; 137:653–62.
36.
RubinEHBiggsJTPreskornSH. Nortryptyline pharmacokinetics and plasma levels: Implications for clinical practice. J Clin Psychiatry1985; 46:418–24.
37.
ZeiglerVEBiggsJT. Tricyclic plasma levels: Effects of age, race, sex, and smoking. JAMA1977; 438:2167–9.
38.
OrsulakPJ. Therapeutic monitoring of antidepressant drugs: Guidelines updated. Ther Drug Monit1989; 11:497–507.
39.
GlassmanAHSchildkrautJJOrsulakPJCooperTBKupferDJShaderRI. Tricyclic antidepressant blood level measurements and clinical outcome: An APA task force report. Am J Psychiatry1985; 142:155–62.
40.
NelsonJCJatlowPIQuinlanDM. Desipramine plasma concentration and antidepressant response. Arch Gen Psychiatry1982; 39:1419–22.
41.
NelsonJCJatlowPIMazureC. Desipramine plasma levels and response in elderly melancholic patients. J Clin Psychopharmacol1985; 5:217–20.
